10-K: NanoVibronix Outlines Share Structure and Product Pipeline in Annual Filing

NanoVibronix, Inc. details its capital structure, product development, and regulatory strategies in its annual 10-K filing.

Summary

• NanoVibronix, Inc. is a medical device company focused on non-invasive, biological response-activating devices.
• The company's primary products include UroShield, PainShield, and WoundShield, which utilize low-frequency ultrasound technology.
• As of April 8, 2024, the company has 40,000,000 authorized common shares, with 2,784,354 shares issued and outstanding.
• The company also has 5,040,000 authorized preferred shares, including Series C, D, E, and F, with none currently issued and outstanding.
• The company has a history of losses, with a net loss of approximately $3.7 million in 2023 and an accumulated deficit of approximately $66.1 million.
• The company is seeking FDA approval for UroShield through the De Novo classification process and is working on a non-prescription version of PainShield MD called PainShield Relief.
• The company has entered into a contract with Veranex, Inc. for research and development services to assist with the development of the companys next generation of UroShield and PainShield products with estimated fees and expenses of up to approximately $1.1 million.
• The company has a month-to-month rental program for UroShield and PainShield.
• The company has a reverse stock split of 1-for-20 that was completed on February 8, 2023.

Sentiment

Score: 4

Explanation: The document highlights both positive developments, such as increased revenue and new partnerships, and significant challenges, including ongoing losses, regulatory hurdles, and going concern issues. The overall sentiment is cautiously optimistic, but with a clear awareness of the risks involved.

Positives

• The company has seen a significant increase in revenue in 2023 compared to 2022.
• The company has established distribution partnerships for UroShield in the U.K., Australia, New Zealand, and Malta.
• The company has a contract with NHS Supply Chain for the supply of UroShield.
• The company has a research agreement with the University of Michigan to further advance clinical evidence of the efficacy of UroShield.
• The company has received FDA clearance for PainShield Plus in November 2023.

Negatives

• The company has a history of losses and expects to continue to incur losses.
• The company has substantial doubt about its ability to continue as a going concern.
• The company was denied reimbursement for PainShield by CMS due to a lack of life-cycle testing.
• The company has a limited trading volume for its common stock.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to raise additional capital is uncertain.
• The company faces competition from established medical device companies.
• The company is subject to extensive governmental regulation, including FDA approval.
• The company's operations in Israel are subject to political, economic, and military instability.
• The company's securities may be volatile and the market price may drop below the price paid.
• The company has a significant number of warrants and options that could dilute the stock.
• The company may be delisted from the Nasdaq Capital Market if it fails to comply with listing requirements.
• The company is a smaller reporting company with reduced disclosure obligations.
• The company may be subject to ongoing restrictions related to grants from the Israeli Office of the Chief Scientist.
• The company may be subject to ongoing restrictions related to grants from the Israeli Office of the Chief Scientist.
• The company may be subject to ongoing restrictions related to grants from the Israeli Office of the Chief Scientist.

Future Outlook

The company expects to continue to incur losses for at least the next year as it continues to seek FDA approval for UroShield and market acceptance of PainShield.

Management Comments

• Management has substantial doubt about the Companys ability to continue as a going concern.
• Management believes that the business opportunity for UroShield is in the hundreds of millions in U.S. dollars to the extent that UroShield obtains permanent marketing authorization from the FDA.

Industry Context

The company operates in the competitive medical device industry, facing competition from established companies and new entrants. The company is focused on non-invasive, biological response-activating devices, which is a growing area in the medical device market.

Comparison to Industry Standards

• The company's products, such as PainShield, compete with traditional ultrasound devices from companies like Mettler Electronics Corp, Metron USA and Zimmer MedizinSysteme, which are typically larger and require administration by healthcare professionals.
• The company also competes with smaller ultrasound devices from companies like Koalaty Products, Inc., Sun-Rain System Corp. and PhysioTEC, which generally function at the same frequency and with the same administration and safety requirements as traditional devices.
• The company is aware of ZetrOZ, Inc.'s SAM Sport4 product, which has FDA approval and CE Mark approval, and eliminates some limitations of traditional ultrasound devices, but does not generate surface acoustic waves like NanoVibronix's products.
• The company's WoundShield product competes with wound-healing devices from companies like 3M Company, Smith and Nephew plc, and Convatec Inc., which have greater resources and established distribution networks.
• The company's UroShield product competes with antibiotic-coated and silver-coated catheters, but is designed to be added to any type of catheter to improve infection prevention performance.

Legal Proceedings

• The company is involved in an ongoing legal proceeding with Protrade Systems, Inc. related to a breach of an Exclusive Distribution Agreement.

Related Party Transactions

• The company has paid legal fees to FisherBroyles LLP, where one of its board members is a partner.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial challenges.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers may be impacted by delays in product development and regulatory approvals.
• Suppliers may face uncertainty due to the company's financial situation.

Next Steps

• The company intends to seek long-term marketing authorization from the FDA through the De Novo classification process for UroShield.
• The company intends to seek FDA authorization to market PainShield for a larger range of indications.
• The company intends to pursue marketing authorization for a non-prescription version of PainShield MD, which it refers to as PainShield Relief.
• The company intends to conduct a community based PRO study (Patient Reported Outcomes) measuring the impact UroShield will have on prevention of CAUTI, prevention of blockage, and prevention of pain.

Key Dates

Keywords

medical devices, ultrasound technology, UroShield, PainShield, WoundShield, FDA approval, clinical trials, reimbursement, capital stock, reverse stock split